Labcorp Holdings Inc. (LH)

Market Cap	20.56B
Revenue (ttm)	13.18B
Net Income (ttm)	730.80M
Shares Out	83.70M
EPS (ttm)	8.67
PE Ratio	28.34
Forward PE	15.01
Dividend	$2.88 (1.17%)
Ex-Dividend Date	Aug 28, 2025

Volume	843,329
Open	249.80
Previous Close	249.80
Day's Range	245.19 - 250.41
52-Week Range	205.98 - 265.72
Beta	0.80
Analysts	Strong Buy
Price Target	274.79 (+11.86%)
Earnings Date	Jul 24, 2025

About LH

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1971
• Employees: 70,000
• Stock Exchange: NYSE
• Ticker Symbol: LH
• Website: https://www.labcorp.com

Financial Performance

In 2024, Labcorp Holdings's revenue was $13.01 billion, an increase of 6.97% compared to the previous year's $12.16 billion. Earnings were $746.00 million, an increase of 78.47%.

Analyst Summary

According to 15 analysts, the average rating for LH stock is "Strong Buy." The 12-month stock price target is $274.79, which is an increase of 11.86% from the latest price.

Price Target

$274.79

(11.86% upside)

Analyst Consensus: Strong Buy